MARKET

CTOR

CTOR

Citius Oncology, Inc.
NASDAQ
0.5095
+0.0094
+1.88%
After Hours: 0.5000 -0.0095 -1.86% 17:20 11/06 EST
OPEN
0.5410
PREV CLOSE
0.5001
HIGH
0.5410
LOW
0.5023
VOLUME
197.44K
TURNOVER
--
52 WEEK HIGH
1.830
52 WEEK LOW
0.4912
MARKET CAP
47.37M
P/E (TTM)
-1.0711
1D
5D
1M
3M
1Y
5Y
1D
Citius Oncology Reports LYMPHIR Quality-of-Life Study Results
TipRanks · 4d ago
Weekly Report: what happened at CTOR last week (1026-1030)?
Weekly Report · 6d ago
Analysts’ Top Healthcare Picks: Citius Oncology (CTOR), Genmab (GMAB)
TipRanks · 10/28 19:20
Citius Oncology Reports Preliminary Q4 FY2026 LYMPHIR Wholesaler Unit Sales More Than Doubling 120% To 792 Units, With 950 Institutional Vial Orders And 54 Institutions Ordering The CTCL Treatment
Benzinga · 10/26 17:51
Citius reports 120% growth in shipments of LYMPHIR units to U.S. wholesalers
TipRanks · 10/26 17:05
Weekly Report: what happened at CTOR last week (1019-1023)?
Weekly Report · 10/26 10:14
Citius Oncology Granted Nasdaq Extension to Regain Compliance
TipRanks · 10/23 20:31
Weekly Report: what happened at CTOR last week (1012-1016)?
Weekly Report · 10/19 10:14
More
About CTOR
Citius Oncology, Inc. is a biopharmaceutical company. The Company is focused on developing and commercializing targeted oncology therapies. The Company’s lead product candidate is LYMPHIR, an engineered IL-2 diphtheria toxin fusion protein, for the treatment of patients with persistent or recurrent CTCL, a rare form of non-Hodgkin lymphoma. LYMPHIR is a targeted immune therapy for relapsed or refractory cutaneous T-cell lymphoma (CTCL) indicated for use in Stage I-III disease after at least one prior systemic therapy. It is a recombinant fusion protein that combines the IL-2 receptor binding domain with diphtheria toxin fragments. The agent specifically binds to IL-2 receptors on the cell surface, causing diphtheria toxin fragments that have entered cells to inhibit protein synthesis. After uptake into the cell, the diphtheria toxin (DT) fragment is cleaved and the free DT fragments inhibit protein synthesis, resulting in cell death.

Webull offers Citius Oncology Inc stock information, including NASDAQ: CTOR real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, CTOR stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading CTOR stock methods without spending real money on the virtual paper trading platform.